Research ExplorerPublicationsAberrant expression of the microtubule-associated protein ta...

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer

Standard

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. / Schroeder, Cornelia; Grell, Jan; Hube-Magg, Claudia; Kluth, Martina; Lang, Dagmar; Simon, Ronald; Höflmayer, Doris; Minner, Sarah; Burandt, Eike; Clauditz, Till S; Büscheck, Franziska; Jacobsen, Frank; Huland, Hartwig; Graefen, Markus; Schlomm, Thorsten; Sauter, Guido; Steurer, Stefan.

In: BMC CANCER, Vol. 19, No. 1, 01.03.2019, p. 193.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schroeder, C, Grell, J, Hube-Magg, C, Kluth, M, Lang, D, Simon, R, Höflmayer, D, Minner, S, Burandt, E, Clauditz, TS, Büscheck, F, Jacobsen, F, Huland, H, Graefen, M, Schlomm, T, Sauter, G & Steurer, S 2019, 'Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer', BMC CANCER, vol. 19, no. 1, pp. 193. https://doi.org/10.1186/s12885-019-5390-1

APA

Schroeder, C., Grell, J., Hube-Magg, C., Kluth, M., Lang, D., Simon, R., Höflmayer, D., Minner, S., Burandt, E., Clauditz, T. S., Büscheck, F., Jacobsen, F., Huland, H., Graefen, M., Schlomm, T., Sauter, G., & Steurer, S. (2019). Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. BMC CANCER, 19(1), 193. https://doi.org/10.1186/s12885-019-5390-1

Vancouver

Schroeder C, Grell J, Hube-Magg C, Kluth M, Lang D, Simon R et al. Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. BMC CANCER. 2019 Mar 1;19(1):193. https://doi.org/10.1186/s12885-019-5390-1

Bibtex

@article{fdfb441973d147f6b0bb43ea42d43b79,
title = "Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer",
abstract = "BACKGROUND: Microtubule-associated protein Tau (MAPT) overexpression has been linked to poor prognosis and decreased response to taxane-based therapies in several cancer types, but its relevance in prostate cancer is unknown.METHODS: In this study, MAPT expression was analyzed by immunohistochemistry on a tissue microarray containing 17,747 prostate cancers.RESULTS: MAPT was absent in normal prostate epithelial cells but detectable in 1004 (8.2%) of 12,313 interpretable cancers. Its expression was associated with advanced tumor stage, high Gleason grade, positive lymph nodes, and early biochemical recurrence (p < 0.0001 each). For example, MAPT was found in 3.6% of 2072 Gleason ≤3 + 3 cancers but in 14.4% of 704 Gleason ≥4 + 4 cancers. High-level MAPT staining was also linked to TMPRSS2:ERG fusions (p < 0.0001). MAPT staining was seen in 15.2 and 16% of cancers with TMPRSS2:ERG fusion detected by immunohistochemistry and fluorescence in-situ hybridization, but in only 3.5 and 3.9% of cancers without ERG staining or ERG rearrangements. Moreover, an association was found between MAPT expression and PTEN deletions, with 19% MAPT positivity in 948 PTEN deleted cancers but only 7% MAPT positivity in 3895 tumors with normal PTEN copy numbers (p < 0.0001). Multivariate analysis revealed that the prognostic value of MAPT was independent from established parameters. Conventional large section analyses showed intratumoral MAPT heterogeneity in all three analyzed cancers.CONCLUSIONS: The results of our study identify MAPT, as a moderate prognostic marker in prostate cancer, whose clinical impact, however, may be limited due to the rarity and heterogeneity of its expression.",
keywords = "Humans, Immunohistochemistry, Kallikreins/blood, Lymph Nodes/pathology, Male, Multivariate Analysis, Neoplasm Grading, Neoplasm Recurrence, Local/blood, Neoplasm Staging, Oncogene Proteins, Fusion/genetics, PTEN Phosphohydrolase/genetics, Prognosis, Proportional Hazards Models, Prostate-Specific Antigen/blood, Prostatic Neoplasms/genetics, tau Proteins/metabolism",
author = "Cornelia Schroeder and Jan Grell and Claudia Hube-Magg and Martina Kluth and Dagmar Lang and Ronald Simon and Doris H{\"o}flmayer and Sarah Minner and Eike Burandt and Clauditz, {Till S} and Franziska B{\"u}scheck and Frank Jacobsen and Hartwig Huland and Markus Graefen and Thorsten Schlomm and Guido Sauter and Stefan Steurer",
year = "2019",
month = mar,
day = "1",
doi = "10.1186/s12885-019-5390-1",
language = "English",
volume = "19",
pages = "193",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer

AU - Schroeder, Cornelia

AU - Grell, Jan

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Lang, Dagmar

AU - Simon, Ronald

AU - Höflmayer, Doris

AU - Minner, Sarah

AU - Burandt, Eike

AU - Clauditz, Till S

AU - Büscheck, Franziska

AU - Jacobsen, Frank

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Schlomm, Thorsten

AU - Sauter, Guido

AU - Steurer, Stefan

PY - 2019/3/1

Y1 - 2019/3/1

N2 - BACKGROUND: Microtubule-associated protein Tau (MAPT) overexpression has been linked to poor prognosis and decreased response to taxane-based therapies in several cancer types, but its relevance in prostate cancer is unknown.METHODS: In this study, MAPT expression was analyzed by immunohistochemistry on a tissue microarray containing 17,747 prostate cancers.RESULTS: MAPT was absent in normal prostate epithelial cells but detectable in 1004 (8.2%) of 12,313 interpretable cancers. Its expression was associated with advanced tumor stage, high Gleason grade, positive lymph nodes, and early biochemical recurrence (p < 0.0001 each). For example, MAPT was found in 3.6% of 2072 Gleason ≤3 + 3 cancers but in 14.4% of 704 Gleason ≥4 + 4 cancers. High-level MAPT staining was also linked to TMPRSS2:ERG fusions (p < 0.0001). MAPT staining was seen in 15.2 and 16% of cancers with TMPRSS2:ERG fusion detected by immunohistochemistry and fluorescence in-situ hybridization, but in only 3.5 and 3.9% of cancers without ERG staining or ERG rearrangements. Moreover, an association was found between MAPT expression and PTEN deletions, with 19% MAPT positivity in 948 PTEN deleted cancers but only 7% MAPT positivity in 3895 tumors with normal PTEN copy numbers (p < 0.0001). Multivariate analysis revealed that the prognostic value of MAPT was independent from established parameters. Conventional large section analyses showed intratumoral MAPT heterogeneity in all three analyzed cancers.CONCLUSIONS: The results of our study identify MAPT, as a moderate prognostic marker in prostate cancer, whose clinical impact, however, may be limited due to the rarity and heterogeneity of its expression.

AB - BACKGROUND: Microtubule-associated protein Tau (MAPT) overexpression has been linked to poor prognosis and decreased response to taxane-based therapies in several cancer types, but its relevance in prostate cancer is unknown.METHODS: In this study, MAPT expression was analyzed by immunohistochemistry on a tissue microarray containing 17,747 prostate cancers.RESULTS: MAPT was absent in normal prostate epithelial cells but detectable in 1004 (8.2%) of 12,313 interpretable cancers. Its expression was associated with advanced tumor stage, high Gleason grade, positive lymph nodes, and early biochemical recurrence (p < 0.0001 each). For example, MAPT was found in 3.6% of 2072 Gleason ≤3 + 3 cancers but in 14.4% of 704 Gleason ≥4 + 4 cancers. High-level MAPT staining was also linked to TMPRSS2:ERG fusions (p < 0.0001). MAPT staining was seen in 15.2 and 16% of cancers with TMPRSS2:ERG fusion detected by immunohistochemistry and fluorescence in-situ hybridization, but in only 3.5 and 3.9% of cancers without ERG staining or ERG rearrangements. Moreover, an association was found between MAPT expression and PTEN deletions, with 19% MAPT positivity in 948 PTEN deleted cancers but only 7% MAPT positivity in 3895 tumors with normal PTEN copy numbers (p < 0.0001). Multivariate analysis revealed that the prognostic value of MAPT was independent from established parameters. Conventional large section analyses showed intratumoral MAPT heterogeneity in all three analyzed cancers.CONCLUSIONS: The results of our study identify MAPT, as a moderate prognostic marker in prostate cancer, whose clinical impact, however, may be limited due to the rarity and heterogeneity of its expression.

KW - Humans

KW - Immunohistochemistry

KW - Kallikreins/blood

KW - Lymph Nodes/pathology

KW - Male

KW - Multivariate Analysis

KW - Neoplasm Grading

KW - Neoplasm Recurrence, Local/blood

KW - Neoplasm Staging

KW - Oncogene Proteins, Fusion/genetics

KW - PTEN Phosphohydrolase/genetics

KW - Prognosis

KW - Proportional Hazards Models

KW - Prostate-Specific Antigen/blood

KW - Prostatic Neoplasms/genetics

KW - tau Proteins/metabolism

U2 - 10.1186/s12885-019-5390-1

DO - 10.1186/s12885-019-5390-1

M3 - SCORING: Journal article

C2 - 30823906

VL - 19

SP - 193

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

IS - 1

ER -